143
Participants
Start Date
November 6, 2013
Primary Completion Date
April 4, 2023
Study Completion Date
April 4, 2023
Azacitidine
Entinostat
Nivolumab
CC-486 300
UPMC Cancer Center- Hillman Cancer Center, Pittsburgh
Sibley Memorial Hospital, Washington D.C.
Julie Brahmer, MD, Baltimore
Julie Brahmer, MD, Baltimore
University of Southern California, Los Angeles
Collaborators (4)
Rising Tide Foundation
OTHER
Stand Up To Cancer
OTHER
Bristol-Myers Squibb
INDUSTRY
Celgene
INDUSTRY
Syndax Pharmaceuticals
INDUSTRY
Rhone-Poulenc Rorer
INDUSTRY
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OTHER